

ANNUAL IMPACT REPORT

January 2026 | Prepared for LEO Pharma



THANK YOU TO OUR CORPORATE DONORS

On behalf of the Partnerships Team at IHP, thank you for your invaluable support throughout 2025. This has been a year of unprecedented pressure for the humanitarian sector, with significant aid cuts tightening budgets across the board. Yet even as challenges grew, so did the need for quality healthcare—and thanks to you, IHP was able to continue delivering it.

This year, we marked IHP's 20th anniversary at a Humanitarian Reception at Buckingham Palace, hosted by His Majesty the King and Her Majesty the Queen, where we highlighted our disaster response work and the vital support of the UK and EU pharmaceutical and healthcare sector.

In 2025, we expanded into Sierra Leone and Zimbabwe and launched the Sustainable Healthcare Initiative in Zanzibar with HPIZ, strengthening healthcare systems through targeted, time-bound activities beyond product donations alone.

Even amid tightening budgets, our partners ensured a steady flow of products wherever needs arose, and we are deeply grateful for their continued support.

Other key milestones for IHP included our first-ever vaccine donation, delivering free Hepatitis B

vaccines to 45,000 patients in Ukraine and North Macedonia; a fourfold increase in cold-chain shipments expanding access to oncology treatments; and record-breaking produce-to-give donations supporting rapid disaster response.

As we look toward 2026, we remain committed to expanding healthcare access and championing best practices in medical donations. We hope this report offers a clear view of the impact you have made—the lives transformed, the communities strengthened, and the gratitude shared by the organisations and patients who received these vital medicines and supplies.

Thank you for your continued partnership and trust in IHP.



Lily Jones-Herbst
Partnerships Manager

20 COUNTRIES



International Health Partners shipped medicine and medical supplies across 20 countries in 2025, covering Africa, the Middle East, Central America, the Caribbean and the Balkans

3.1 MILLION




In 2025 IHP supported more than three million patients globally. Providing healthcare support across a broad range of needs, from primary health care through to cancer treatment.

£16.8 MILLION



Together with the support of our partners, we donated over £16 million worth of medicines and medical supplies to vulnerable communities around the world

THE IHP PROCESS



OUR VISION: THE BRIDGE



2026

This year has underscored both the urgency and the complexity of IHP's mission. As global demand for essential medical products continues to grow, the systems that support access—funding, supply chains, and operational capacity—have become increasingly strained. In this challenging environment, IHP's role as The Bridge has never been more vital.

Throughout 2025, we strengthened what defines us: our ability to connect the healthcare industry with trusted in-country partners so that life-changing treatments reach people affected by conflict, crisis, and fragile health systems. Acting as an expert, neutral intermediary, we ensure every product we facilitate is appropriate, safe, and responsibly delivered—turning intent into impact by navigating the risk and complexity that sits between supply and need.

Our impact this year is reflected not only in the volumes of medicines delivered, but also in the partnerships deepened, systems strengthened, and strategic clarity gained. These foundations—often invisible but essential—enable us to keep operating where the need is greatest.

As global health challenges become more intricate, the world needs credible organisations capable of bridging divides and enabling collaboration. Through a year of significant review and organisational reshaping, we have reinforced that bridge, positioning IHP to continue delivering access to healthcare for those who need it most.

IHP's strategy this year focuses on strengthening our identity as the Bridge between product donors and implementing partners, with the focus on maximising the Flow of product across the IHP Bridge in order to reach those in greatest need. This is a return to IHP's founding USP.

As part of this, IHP is expanding its operations into the EU (following Brexit) to restore and expand our ability to receive, process, and export medicines in and from Europe – unlocking partnerships and access that had previously been restricted. Our registration in Europe will enable us to deepen our impact and extend our reach. We have submitted our EU Charity and WDA license applications, and will soon be processing shipments from our Netherlands warehouse. We welcome our corporate donors with EU presence to support us in this journey.

Thank you for your continued support and partnership.

LEO PHARMA 2025 IMPACT

**HONDURAS
NORTH MACEDONIA
SYRIA**

4 SHIPMENTS



of medicine delivered across 3 countries

92,032 UNITS



of medicine donated in 2025 by LEO Pharma

£704,779



worth of medicine donated by LEO Pharma in 2025

94,537 PATIENTS



supported as a result of LEO Pharma's donations

HONDURAS



Provision of healthcare in Honduras faces significant challenges, particularly in rural areas where access to basic health services remains limited and residents often must travel long distances for care. The public system, overseen by the Ministry of Health, struggles with underfunding, shortages of healthcare professionals, and inadequate infrastructure, resulting in disparities in quality and availability of care across the country.

HIDA works through their local partner, Proyecto Aldea Global (PAG), in Honduras. PAG's health programme operates across central and western Honduras, supporting approximately 130 health facilities in the central region and around 40 in the west. These include public hospitals, regional health units, and community clinics.

The creams donated by LEO Pharma will be distributed through PAG's community pharmacies, which are located in more remote and rural areas. These pharmacies are run by trained community volunteers, significantly improving access to healthcare by reducing the need for long, costly journeys to larger cities.

The Heparin solution will be distributed to government-run hospitals, which frequently experience stockouts due to inconsistent supply from the government. This donation therefore plays a highly impactful role in filling these critical gaps.

Thank you to LEO Pharma for your generous support in strengthening healthcare access for underserved communities in Honduras.

OUR PARTNER



HOPE
International
Development Agency



NORTH MACEDONIA



OUR PARTNER

project
HOPE

The donation was distributed at the University Clinical Center in Skopje. The needs are immense, as these are tertiary healthcare institutions responsible for treating the majority of related cases in the country.

Due to severe underfunding, primary and secondary healthcare facilities often lack the capacity to treat patients, resulting in most cases being referred to the main clinical center in Skopje.

The new healthcare agenda emphasizes strengthening primary and secondary care by improving service delivery, regional coverage, and budgeting. However, this remains largely a conceptual plan.

Project HOPE's Strategic Medical Re-Supply Program (SMRP) is a long-standing, high-impact initiative that has significantly strengthened healthcare delivery in Kosovo and Macedonia over the past 20 years. Through a strategic and needs-based approach, the program has delivered over \$170 million worth of donated medical products, helping to fill critical gaps in the healthcare systems, generate substantial budget savings, and introduce treatments not otherwise available on the local market.

Ultimately, SMRP stands as a lifesaving and system-supporting program, enabling hospitals to deliver care under challenging circumstances, and contributing to more equitable, resilient, and sustainable health systems in the region.

We met with the Dermatology clinic staff in a Project HOPE and IHP supported hospital in North Macedonia to hear about the recent donation of healthcare products from **LEO Pharma**.

Dr Peshic explained that the donation from IHP has a huge impact on the work of the hospital and the patients. In particular, they noted the effectiveness of Xamiol gel for patients with psoriasis. Combined with UV treatments, the team shared that the results have been fantastic- clearing skin completely. Fito cream and Fito Gauzes for patients with varicose veins have also given great results.

The team also shared that the donation was used to treat the survivors of the fire in the nightclub in Kochani. The Fito and Advantan creams are all being used to support their treatment process.

The impact of the donation on the quality of care at the hospital has been significant, and thanks to the donation, the hospital has been able to invest in infrastructure improvements to improve their services.

SYRIA



Displacement, protracted conflict, and financial instability create profound challenges for health. These pressures affect both mental and physical health, increasing rates of chronic illness, acute infections, and unmet medical needs. Children are particularly vulnerable, with disrupted access to vaccines, essential medicines, and proper nutrition increasing the risk of preventable illness and long-term health conditions.

Against this backdrop, access to medicines remains limited. Consultations with the Ministry of Public Health (MoPH) have confirmed that only around 20% of the country's medication needs are currently being met. These gaps place lives at risk and significantly constrain the ability of health facilities to respond to both routine and emergency needs.

OUR PARTNER



SAMS



Through the consistent support and comprehensive care provided by SAMS, patients have been able to break this cycle and rebuild their lives. SAMS offers not only medical treatment—including access to medicines, pediatric care, and chronic disease management—but also psychosocial support, helping individuals restore balance, regain confidence, and reconnect with their communities. Children who once struggled with untreated conditions have reported significant improvements in growth, energy, and school participation, while adults have experienced better management of chronic illnesses and recovery from acute health crises.

This impact demonstrates the critical importance of accessible, holistic healthcare in times of crisis. By addressing both the medical and social dimensions of health—including mental wellbeing, child health, and access to essential medicines—IHP, SAMS, and our partners empower patients to move beyond survival toward resilience and long-term wellbeing.



SYRIA

Thanks to donors, like LEO Pharma, IHP is able to supply medications supported by partners to IDPs and host communities, including the elderly, pregnant women, children, and people with disabilities



"The medications provided by IHP have been incredibly beneficial given the severe shortage of medicines in Northwest and Northcentral Syria. Finding all necessary medications in the region has been a significant challenge. These medications were distributed for free, which was especially vital for patients with chronic diseases who need them regularly. With the financial difficulties in securing these medications, IHP's donation was a tremendous effort. It has proven to be highly useful and effective. Many thanks for this generous donation." - SAMS



**A BIG THANK
YOU TO LEO PHARMA**

IMPROVING ACCESS TO HEALTHCARE



Your support has made the provision of these lifesaving services possible. Because of you, millions of people around the world received the medicines they needed when they needed them. Thank you for joining with us to improve access to healthcare to all



l.jones-herbst@ihpuk.org | www.ihpuk.org | Tel: 020 3735 5489

Fox Court, 14 Gray's Inn Road, London, WC1X 8HN

Charity number: 1105455 | Company number: 05044723

© International Health Partners